Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: George Mc Geary who wrote (949)	7/18/2000 10:13:51 AM
From: Ian@SI	Read Replies (2) \| Respond to of 1321

George, There's another story in today's National Post with interviews from both analysts that downgraded QLT as well as comments from the CIBC World Markets analyst. So far, I haven't seen any argument that will convince me that QLT's Visudyne will be anything less than a $1B blockbuster. No person who is going blind is going to postpone the only treatment that works. This disease has been untreatable in the past. Doctors have actually used high power lasers to burn a hole through the macula in an attempt to get at and destroy the abnormal blood vessels behind it. While I believe they've stopped this barbaric practice in the states - it only causes immediate loss of vision without stopping disease progression - some retinal specialists still do it in Canada today. There is no other treatment. People will never choose to go blind. Any analyst that can't understand that, should switch professions. Ian.